Preclinical Biologics for Companion Animal Health
Single-Domain Antibodies Based Biologics Platform
Based in the south of France and founded in 2026, PawGenX is a preclinical biotech company supported by the Impulse incubator.
The company leverages state-of-the-art biologics engineering and computational design to develop therapeutic candidates for companion animals.
Its technology is built around single-domain antibody formats, offering favorable properties in terms of stability, engineering flexibility, and suitability for preclinical development.
The approach emphasizes molecular quality, developability, and translational relevance from early discovery through preclinical evaluation, enabling efficient advancement toward partnering and licensing.
Modular Single-Domain Antibody Architectures
Single-domain antibodies provide a compact and highly engineerable binding module.
PawGenX leverages this modularity to design differentiated molecular formats optimized for species alignment, durability, and efficient dosing paradigms, supporting cost-efficient development compared with conventional antibody approaches.
AI-Guided Engineering & Translation-Focused Cellular Assays
PawGenX integrates computational and AI-supported design to guide engineering choices, including species-specific sequence optimization and early multi-parameter asset optimization.
In parallel, we develop differentiated, translation-oriented cellular assays to generate decision-grade functional data early—supporting mechanism-relevant readouts and informed selection of assets with disease-modifying potentialPartnering-Ready Preclinical Design
PawGenX builds preclinical asset profiles and data packages aligned with pharmaceutical partnering standards, with a focus on species relevance, differentiation, durability, and translational confidence.
This approach is designed to support disease-modifying strategies and efficient dosing while advancing high-value assets toward strategic licensing.
